Patent · US Active

Use of a quinazoline compound in preparing a medicament against flaviviridae virus

US9133138B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignee

SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN

Inventors

Jianping Zuo · Shanghai, CN
Youhong Hu · Shanghai, CN
Wei Tang · Shanghai, CN
Bo Chao · Summit, US
Xiankun Tong · Shanghai, CN
Dewen Li · Jingwei, CN
Feihong Ji · Shanghai, CN
Peilan He · Shanghai, CN

Key dates

Filing date	Dec 2, 2011
Grant date	Sep 15, 2015
Priority date	—
Expiry date	Dec 6, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.